{"id":47535,"date":"2026-05-26T11:33:31","date_gmt":"2026-05-26T09:33:31","guid":{"rendered":"https:\/\/hempika.com\/?page_id=47535"},"modified":"2026-06-04T15:24:33","modified_gmt":"2026-06-04T13:24:33","slug":"cannabinoids-101","status":"publish","type":"page","link":"https:\/\/hempika.com\/en\/cannabinoids-101\/","title":{"rendered":"Cannabinoids 101"},"content":{"rendered":"<article>\n<div class=\"h-101\">\n<div class=\"h-101-top\">\n<h1>Cannabinoids 101<\/h1>\n<p><em>Everything you need to know about what cannabinoids are, how they work, and why they matter: from plant chemistry to your body&#8217;s own endocannabinoid system.<\/em><\/p>\n<p>  <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/hempika.com\/wp-content\/themes\/hemp-master\/assets\/img\/cannabinoids-101.png\" alt=\"Cannabinoids 101\" width=\"100\" height=\"100\"><\/p>\n<\/div>\n<div class=\"h-101-left\">\n<nav>\n<h2>Table of Contents<\/h2>\n<ol>\n<li><a href=\"#what-are-cannabinoids\">What are cannabinoids?<\/a><\/li>\n<li><a href=\"#how-cannabinoids-are-made\">How cannabinoids are made?<\/a><\/li>\n<li><a href=\"#the-endocannabinoid-system\">The endocannabinoid system<\/a><\/li>\n<li><a href=\"#phytocannabinoids\">Phytocannabinoids: The main players<\/a><\/li>\n<li><a href=\"#endocannabinoids\">Endocannabinoids: Your body&#8217;s own version<\/a><\/li>\n<li><a href=\"#synthetic-cannabinoids\">Synthetic cannabinoids<\/a><\/li>\n<li><a href=\"#the-entourage-effect\">The entourage effect<\/a><\/li>\n<li><a href=\"#cannabinoids-and-the-body\">Cannabinoids and the body: What research says?<\/a><\/li>\n<li><a href=\"#full-spectrum-vs-broad-spectrum-vs-isolate\">Types of cannabinoid extracts<\/a><\/li>\n<li><a href=\"#legal-status\">Legal status by cannabinoid<\/a><\/li>\n<\/ol>\n<\/nav>\n<\/div>\n<div class=\"h-101-right\">\n<section id=\"what-are-cannabinoids\">\n<h2>1. What are cannabinoids?<\/h2>\n<p>Cannabinoids are a class of chemical compounds that interact with a network of receptors found throughout the human body and nervous system. They are best known for their presence in the cannabis plant, but the story goes far deeper than that.<\/p>\n<p>Scientists have identified over 100 distinct cannabinoids in <em>Cannabis sativa<\/em> alone. Each one has a slightly different molecular shape, and that shape determines how it interacts with your body&#8217;s receptors, what effects it produces, and how potent those effects are.<\/p>\n<p>There are three types of cannabinoids, and it is worth understanding all three from the outset:<\/p>\n<ul>\n<li><strong>Phytocannabinoids<\/strong> are produced naturally by plants, most notably <em>Cannabis sativa<\/em>, but also found in small amounts in black pepper, echinacea, and cacao.<\/li>\n<li><strong>Endocannabinoids<\/strong> are produced on demand by the human body itself. These are your body&#8217;s native signalling molecules for the same receptor system.<\/li>\n<li><strong>Synthetic cannabinoids<\/strong> are created in a laboratory, either for pharmaceutical purposes or, in dangerous forms, as recreational drugs.<\/li>\n<\/ul>\n<p>When most people talk about cannabinoids, they mean phytocannabinoids, and specifically those derived from <a href=\"https:\/\/hempika.com\/en\/hemp-101\/\">hemp<\/a>. The two most well-known are <strong>CBD (cannabidiol)<\/strong> and <strong>THC (tetrahydrocannabinol)<\/strong>. But as research advances, a growing number of minor cannabinoids, including CBG, CBN, CBC, and THCV, are drawing serious scientific and commercial interest.<\/p>\n<\/section>\n<section id=\"how-cannabinoids-are-made\">\n<h2>2. How cannabinoids are made?<\/h2>\n<p>Understanding how the cannabis plant synthesises cannabinoids helps explain why different hemp products look, smell, and behave so differently, and why raw, unheated <a href=\"https:\/\/hempika.com\/en\/product\/hemp-flowers\/\">hemp flower<\/a> contains different compounds than a <a href=\"https:\/\/hempika.com\/en\/product\/cbd-drops\/\">CBD oil<\/a>.<\/p>\n<h3>The CBGA starting point<\/h3>\n<p>All cannabinoids begin life as <strong>cannabigerolic acid (CBGA)<\/strong>, sometimes called the &#8220;mother cannabinoid.&#8221; CBGA is produced from two simpler precursors, olivetolic acid and geranyl pyrophosphate, through a chemical reaction inside the plant&#8217;s trichomes (the tiny, glandular hairs covering the flowers and leaves).<\/p>\n<p>From CBGA, specific plant enzymes convert it into three main acidic precursors:<\/p>\n<ul>\n<li><strong>CBDA<\/strong> (cannabidiolic acid) is the precursor to CBD<\/li>\n<li><strong>THCA<\/strong> (tetrahydrocannabinolic acid) is the precursor to THC<\/li>\n<li><strong>CBCA<\/strong> (cannabichromenic acid) is the precursor to CBC<\/li>\n<\/ul>\n<p>Any CBGA that is not converted by these enzymes can itself become CBG through decarboxylation.<\/p>\n<h3>Decarboxylation: activating cannabinoids<\/h3>\n<p>In their raw, natural state, cannabinoids exist as acids. CBDA is not the same as CBD, and THCA is not psychoactive in the way THC is. The transformation from acidic to active form happens through <strong>decarboxylation<\/strong>: the removal of a carboxyl group (COOH), releasing CO&#x2082;.<\/p>\n<p>This happens naturally when cannabis plant material is:<\/p>\n<ul>\n<li><strong>Heated<\/strong> (smoking, vaping, cooking)<\/li>\n<li><strong>Exposed to prolonged light or air<\/strong> (a slower process over time)<\/li>\n<\/ul>\n<p>This is why CBD oils made from hemp extract are typically decarboxylated during processing, to ensure the CBD is in its active, usable form. It is also why raw hemp leaf used in juices or capsules contains CBDA rather than CBD, and why some products are specifically formulated to preserve the raw acidic forms.<\/p>\n<\/section>\n<section id=\"the-endocannabinoid-system\">\n<h2>3. The endocannabinoid system<\/h2>\n<p>The endocannabinoid system (ECS) is one of the most widespread and important regulatory systems in the human body. Yet it was only discovered in the early 1990s, relatively recently in scientific terms, which is why it remains less well understood than systems like the cardiovascular or nervous system.<\/p>\n<p>The ECS has three main components:<\/p>\n<ol>\n<li><strong>Endocannabinoids<\/strong> are signalling molecules produced by your body<\/li>\n<li><strong>Cannabinoid receptors<\/strong> are proteins on cell surfaces that endocannabinoids and phytocannabinoids bind to<\/li>\n<li><strong>Enzymes<\/strong> are responsible for synthesising endocannabinoids when needed and breaking them down once they have done their job<\/li>\n<\/ol>\n<h3>CB1 receptors<\/h3>\n<p>CB1 receptors are found predominantly in the brain and central nervous system, particularly in areas governing memory, coordination, pain processing, and appetite. They are among the most abundant receptors in the brain overall. When THC binds to CB1 receptors, it produces the characteristic psychoactive effects of cannabis. CBD, by contrast, has very low affinity for CB1 receptors, which is why it does not cause intoxication.<\/p>\n<h3>CB2 receptors<\/h3>\n<p>CB2 receptors are distributed mainly throughout the immune system and peripheral tissues, including the gut, spleen, liver, and skin. They play a key role in regulating inflammation and immune responses. Compounds that target CB2 receptors are of particular interest in research into inflammatory conditions.<\/p>\n<h3>Beyond CB1 and CB2<\/h3>\n<p>Research has revealed that cannabinoids interact with a broader range of receptor targets beyond the two classical cannabinoid receptors:<\/p>\n<ul>\n<li><strong>TRPV1<\/strong> (transient receptor potential vanilloid 1) is involved in pain signalling and body temperature regulation. CBD is a known TRPV1 agonist.<\/li>\n<li><strong>5-HT1A<\/strong> (serotonin receptor) is relevant to mood regulation and anxiety. CBD has been shown to activate this receptor, which may partly explain its effects on anxiety.<\/li>\n<li><strong>GPR55<\/strong>, sometimes called the &#8220;third cannabinoid receptor,&#8221; is involved in bone density, blood pressure, and pain.<\/li>\n<li><strong>PPAR&#x03B3;<\/strong> is a nuclear receptor involved in metabolism, inflammation, and cell proliferation.<\/li>\n<\/ul>\n<h3>What the ECS actually does?<\/h3>\n<p>The ECS is sometimes described as a master regulator, a system that helps keep the body in balance (homeostasis). It has documented roles in:<\/p>\n<ul>\n<li>Pain and inflammation<\/li>\n<li>Mood and emotional response<\/li>\n<li>Memory and learning<\/li>\n<li>Appetite and metabolism<\/li>\n<li>Sleep cycles<\/li>\n<li>Immune function<\/li>\n<li>Stress responses<\/li>\n<li>Neuroprotection<\/li>\n<\/ul>\n<p>An important distinction: unlike most neurotransmitter systems, the ECS operates in <strong>reverse<\/strong>. When a post-synaptic neuron becomes overactive, it sends endocannabinoids backwards to the pre-synaptic neuron to slow down the signal. This retrograde signalling makes cannabinoids uniquely positioned as a kind of biological braking system.<\/p>\n<\/section>\n<section id=\"phytocannabinoids\">\n<h2>4. Phytocannabinoids: The main players<\/h2>\n<p>Here is a profile of the most significant cannabinoids found in hemp and the wider cannabis plant.<\/p>\n<h3>CBD (Cannabidiol)<\/h3>\n<p><a href=\"https:\/\/hempika.com\/en\/cbd-101\">CBD<\/a> is the dominant cannabinoid in legal hemp and the most researched non-intoxicating compound in the plant. It does not bind strongly to CB1 or CB2 receptors in the classical sense. Instead, it modulates the ECS indirectly by inhibiting the enzyme FAAH (which breaks down the endocannabinoid anandamide), activating TRPV1 and 5-HT1A receptors, and acting as a negative allosteric modulator at CB1 (meaning it can actually reduce the effects of THC when both are present).<\/p>\n<p>Research into CBD is more advanced than any other cannabinoid. The most robust clinical evidence is in epilepsy: the pharmaceutical CBD product Epidiolex is FDA-approved for two rare forms of childhood epilepsy (Dravet syndrome and Lennox-Gastaut syndrome). Beyond this, a large body of preclinical and human research is investigating CBD for anxiety, sleep, inflammation, pain, and neuroprotection.<\/p>\n<p><strong>Legal status:<\/strong> In the EU, CBD products derived from approved hemp varieties are legal to sell as food supplements, provided they comply with Novel Food regulations and contain less than the nationally specified THC threshold (typically 0.2&#8211;0.3%).<\/p>\n<h3>THC (Delta-9-Tetrahydrocannabinol)<\/h3>\n<p>THC is the primary psychoactive cannabinoid in cannabis. It binds directly and strongly to CB1 receptors in the brain, producing the intoxicating effects associated with marijuana. In the hemp plant, THC is present in only trace quantities. The legal threshold in the EU is 0.3% in dried flower, and finished products must typically contain less than 0.2% (this varies by country).<\/p>\n<p>Despite its reputation, THC is also the subject of legitimate medical research and is the active ingredient in approved pharmaceutical products for nausea (dronabinol) and as a combination therapy (Sativex, which contains a 1:1 THC:CBD ratio) for multiple sclerosis-related spasticity.<\/p>\n<p><strong>Legal status:<\/strong> Controlled substance at concentrations above defined thresholds in most jurisdictions. Present only in trace amounts in legal hemp products.<\/p>\n<h3>CBG (Cannabigerol)<\/h3>\n<p>As the direct decarboxylation product of CBGA (the &#8220;mother cannabinoid&#8221;), CBG has earned its own title as a precursor molecule. In mature cannabis plants, most CBGA has already been converted to other cannabinoids, so CBG is typically present in small quantities, unless the plant has been specifically bred to retain it. Hemp cultivars developed for high CBG content now exist and are driving a new wave of CBG products such as <a href=\"https:\/\/hempika.com\/en\/product\/cbg-drops\/\">CBG drops<\/a> and <a href=\"https:\/\/hempika.com\/en\/product\/cbg-isolate\/\">CBG isolate<\/a>.<\/p>\n<p>CBG interacts with both CB1 and CB2 receptors and also inhibits the reuptake of GABA, a calming neurotransmitter. Preclinical research has explored CBG for its potential antibacterial, anti-inflammatory, and neuroprotective properties. Human clinical data is still limited but growing.<\/p>\n<p><strong>Legal status:<\/strong> Not scheduled as a controlled substance in most jurisdictions; legal in hemp-derived products in the EU.<\/p>\n<h3>CBN (Cannabinol)<\/h3>\n<p>CBN is formed as THC oxidises over time. It is, essentially, aged THC. Hemp flower that has been exposed to heat, light, or air will gradually accumulate CBN. Despite this origin, CBN has very weak psychoactive properties and is generally considered non-intoxicating at the levels found in hemp products.<\/p>\n<p>CBN has attracted interest primarily in the area of sleep, based on early research and anecdotal reports. However, the human clinical evidence base is still thin, and much of the popular claim that &#8220;CBN is a sleep cannabinoid&#8221; rests on small or preclinical studies. It also shows some potential as an antibacterial agent.<\/p>\n<p><strong>Legal status:<\/strong> Generally legal in hemp-derived products; not widely scheduled independently of THC.<\/p>\n<h3>CBC (Cannabichromene)<\/h3>\n<p>CBC is the third most abundant cannabinoid in most cannabis strains, after THC and CBD, though it often appears in only small quantities. It does not bind significantly to CB1 or CB2 receptors but instead interacts with other receptor targets including TRPV1 and TRPA1, both involved in pain signalling.<\/p>\n<p>CBC has been studied for anti-inflammatory, antidepressant, and neuroprotective properties in preclinical settings, and is of particular interest in combination with other cannabinoids (the entourage effect). Like CBG, it remains understudied in humans.<\/p>\n<p><strong>Legal status:<\/strong> Not scheduled; legal in hemp-derived products.<\/p>\n<h3>THCV (Tetrahydrocannabivarin)<\/h3>\n<p>THCV shares a similar molecular structure to THC but has a shorter side chain, which changes how it interacts with CB1 receptors. At low doses, THCV may act as a CB1 antagonist (blocking effects), while at higher doses it may act more like a weak agonist. This has generated interest in THCV as a potential tool for appetite regulation, blood sugar control, and weight management.<\/p>\n<p>THCV is found in very low concentrations in most hemp varieties and is typically only meaningful in specific African cannabis strains. It is one of the more difficult cannabinoids to source in significant quantities.<\/p>\n<p><strong>Legal status:<\/strong> Ambiguous in some jurisdictions. Due to its structural similarity to THC, it faces regulatory scrutiny in several countries.<\/p>\n<h3>CBDA and THCA: The Raw Acidic Forms<\/h3>\n<p>These acidic precursors (the &#8220;A&#8221; stands for acid) are increasingly of interest in their own right, not just as intermediates. CBDA has shown anti-nausea and anti-anxiety properties in preclinical models, potentially with even greater potency at certain receptor targets than CBD itself. THCA, despite being non-psychoactive in raw form, has shown anti-inflammatory and neuroprotective properties in early research.<\/p>\n<p>Products designed to preserve raw cannabinoid acids must avoid heat and are typically stored differently from standard CBD oils. Our <a href=\"https:\/\/hempika.com\/en\/product\/hemp-flowers\/\">hemp flowers<\/a> contain the full spectrum of cannabinoid acids in their natural, unprocessed form.<\/p>\n<\/section>\n<section id=\"endocannabinoids\">\n<h2>5. Endocannabinoids: Your body&#8217;s own version<\/h2>\n<p>Phytocannabinoids are fascinating partly because they work so effectively in the human body, and the reason they do is that our bodies already have a system built around equivalent molecules that we produce ourselves.<\/p>\n<p>The two primary endocannabinoids are:<\/p>\n<h3>Anandamide (AEA)<\/h3>\n<p>Named from the Sanskrit word <em>ananda<\/em> meaning &#8220;bliss,&#8221; anandamide was the first endocannabinoid to be discovered (1992, by Raphael Mechoulam&#8217;s team). It binds to CB1 receptors and plays roles in mood regulation, memory, pain sensation, and even the neurological changes associated with the &#8220;runner&#8217;s high,&#8221; which researchers now believe is more attributable to anandamide than to endorphins.<\/p>\n<p>Anandamide is produced on demand and broken down rapidly by the enzyme FAAH. CBD inhibits FAAH, meaning CBD effectively prolongs the time anandamide stays active in the system. This is one of the primary mechanisms by which CBD may influence mood and pain perception indirectly.<\/p>\n<h3>2-Arachidonoylglycerol (2-AG)<\/h3>\n<p>2-AG is present in the brain at concentrations far higher than anandamide and is the primary endogenous ligand (binding molecule) for both CB1 and CB2 receptors. It plays a central role in neuroprotection, appetite regulation, and immune function. 2-AG is broken down by the enzyme MAGL (monoacylglycerol lipase).<\/p>\n<h3>Clinical endocannabinoid deficiency (CECD)<\/h3>\n<p>Some researchers, notably Dr Ethan Russo, have proposed the theory of clinical endocannabinoid deficiency, the hypothesis that some people have a chronically underactive ECS, which could contribute to conditions including migraine, fibromyalgia, and irritable bowel syndrome. This remains a hypothesis rather than an established clinical diagnosis, but it provides one theoretical framework for why plant-derived cannabinoids might provide relief for some individuals with these conditions.<\/p>\n<\/section>\n<section id=\"synthetic-cannabinoids\">\n<h2>6. Synthetic cannabinoids<\/h2>\n<p>Not all cannabinoids come from plants or from our own bodies. Two very different categories of synthetic cannabinoids are worth understanding clearly.<\/p>\n<h3>Pharmaceutical synthetics<\/h3>\n<p>Legitimate pharmaceutical cannabinoids have been developed to treat specific medical conditions. These include <strong>dronabinol<\/strong> (synthetic THC, used for chemotherapy-induced nausea and AIDS-related appetite loss), <strong>nabilone<\/strong> (a THC analogue used for nausea), and <strong>nabiximols<\/strong> (Sativex, a botanical extract standardised as a pharmaceutical). These are prescribed medicines, tightly regulated, and used under medical supervision.<\/p>\n<h3>Dangerous synthetic cannabinoids<\/h3>\n<p>Often sold as &#8220;herbal incense&#8221; or &#8220;legal highs&#8221; under brand names like Spice, K2, or Mamba, these are entirely different compounds, usually designed to mimic THC but with far greater and more unpredictable receptor binding. They have been associated with severe adverse reactions, psychosis, cardiac events, and deaths. They have no relationship to hemp-derived cannabinoids and should never be confused with them.<\/p>\n<\/section>\n<section id=\"the-entourage-effect\">\n<h2>7. The entourage effect<\/h2>\n<p>One of the most discussed (and debated) concepts in cannabinoid science is the <strong>entourage effect<\/strong>: the hypothesis that cannabinoids, terpenes, and other plant compounds work better together than any single compound in isolation.<\/p>\n<p>The concept was developed most thoroughly by Dr Raphael Mechoulam and Dr Ethan Russo. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3165946\/\" target=\"_blank\" rel=\"noopener\">Russo&#8217;s influential 2011 paper in the <em>British Journal of Pharmacology<\/em><\/a> argued that the phytochemical diversity of cannabis gives full-plant extracts a broader range of therapeutic action than pure CBD or THC alone. The theory suggests that terpenes such as myrcene, limonene, and beta-caryophyllene modulate and enhance the effects of cannabinoids. Beta-caryophyllene, notably, is itself a CB2 agonist.<\/p>\n<h3>What the evidence actually says<\/h3>\n<p>It is important to be balanced here. The entourage effect is biologically plausible and supported by a body of preclinical (animal and cell) studies. However, robust clinical trial evidence in humans comparing full-spectrum extracts to isolates is still limited. Several trials of epilepsy treatment have used whole-plant extracts, and a growing number of researchers support the principle of botanical synergy. That said, the idea that full-spectrum is always superior to isolate for every person and every use case is an oversimplification.<\/p>\n<p>What the entourage theory does suggest, and where there is reasonable scientific consensus, is that the chemical complexity of hemp is more than the sum of its parts, and that discarding minor cannabinoids and terpenes in favour of pure CBD may strip away potentially useful components.<\/p>\n<\/section>\n<section id=\"cannabinoids-and-the-body\">\n<h2>8. Cannabinoids and the body: What research says?<\/h2>\n<p>Here is an honest, evidence-tiered summary of what science currently supports.<\/p>\n<h3>Strong clinical evidence<\/h3>\n<p><strong>Epilepsy<\/strong> is the area with the most robust evidence. Epidiolex (purified CBD) is approved by the US FDA and the EMA for Dravet syndrome and Lennox-Gastaut syndrome. In clinical trials, it significantly reduced seizure frequency compared to placebo. This is landmark evidence: a cannabinoid compound licensed as a prescription medicine based on Phase III trials.<\/p>\n<h3>Moderate and growing evidence<\/h3>\n<p><strong>Anxiety<\/strong> is among the most researched non-epilepsy applications. Multiple controlled human studies have demonstrated that CBD can reduce anxiety in social anxiety disorder contexts, public speaking tasks, and generalised anxiety models. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6326553\/\" target=\"_blank\" rel=\"noopener\">A widely cited 2019 study (Shannon et al.) published in <em>The Permanente Journal<\/em><\/a> found that 79% of patients reported decreased anxiety scores over the first month of CBD supplementation. The authors note that these were promising but preliminary findings, and that randomised controlled trials are still needed.<\/p>\n<p><strong>Sleep<\/strong> is closely linked to anxiety, and several studies have found improvements in sleep quality with CBD use, particularly in patients whose sleep problems were secondary to anxiety. Evidence for CBD as a primary sleep treatment in otherwise healthy individuals is less established.<\/p>\n<p><strong>Pain and inflammation<\/strong> are among the most commonly cited reasons people use CBD, and preclinical evidence is substantial. Human clinical evidence is growing but more mixed. A number of studies have found meaningful pain reduction in chronic pain patients, and the combination product Sativex (CBD + THC) has demonstrated efficacy for neuropathic pain and MS-related spasticity in clinical trials.<\/p>\n<h3>Early-stage and preclinical research<\/h3>\n<p><strong>Neuroprotection:<\/strong> CBD has shown neuroprotective properties in cell and animal models for conditions including Alzheimer&#8217;s, Parkinson&#8217;s, and traumatic brain injury. Human trials are at very early stages.<\/p>\n<p><strong>Skin conditions:<\/strong> Topical cannabinoids have shown anti-inflammatory effects in acne and psoriasis research, and several dermatology-focused clinical trials are underway.<\/p>\n<p><strong>Addiction and substance use:<\/strong> Preliminary evidence suggests CBD may reduce cue-induced craving in people with opioid use disorder. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31109198\/\" target=\"_blank\" rel=\"noopener\">A 2019 double-blind randomised placebo-controlled trial by Hurd et al., published in <em>The American Journal of Psychiatry<\/em><\/a>, found that CBD significantly reduced cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder. The researchers also observed reductions in physiological stress markers including heart rate and cortisol levels.<\/p>\n<p><em><strong>Important notice:<\/strong> Under EU law (and in most jurisdictions), cannabinoid products sold as food supplements cannot make specific medical claims. Nothing on this page should be interpreted as medical advice or as a claim that cannabinoids diagnose, treat, or cure any disease. If you have a medical condition, always consult a qualified healthcare professional.<\/em><\/p>\n<\/section>\n<section id=\"full-spectrum-vs-broad-spectrum-vs-isolate\">\n<h2>9. Types of cannabinoid extracts<\/h2>\n<p>This is one of the most practically important distinctions for anyone buying cannabinoid products.<\/p>\n<table>\n<thead>\n<tr>\n<th><\/th>\n<th>Full-Spectrum<\/th>\n<th>Broad-Spectrum<\/th>\n<th>Isolate<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>CBD<\/strong><\/td>\n<td>Yes<\/td>\n<td>Yes<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td><strong>Other cannabinoids<\/strong><\/td>\n<td>Yes (CBG, CBN, CBC, etc.)<\/td>\n<td>Yes (THC removed)<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td><strong>Terpenes<\/strong><\/td>\n<td>Yes<\/td>\n<td>Yes (usually)<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td><strong>THC<\/strong><\/td>\n<td>Trace amounts (up to 0.2%)<\/td>\n<td>Not detected<\/td>\n<td>None<\/td>\n<\/tr>\n<tr>\n<td><strong>Entourage effect<\/strong><\/td>\n<td>Full potential<\/td>\n<td>Partial<\/td>\n<td>None<\/td>\n<\/tr>\n<tr>\n<td><strong>Drug test risk<\/strong><\/td>\n<td>Low but possible<\/td>\n<td>Very low<\/td>\n<td>Minimal<\/td>\n<\/tr>\n<tr>\n<td><strong>Best for<\/strong><\/td>\n<td>Maximum whole-plant benefit<\/td>\n<td>THC-sensitive individuals<\/td>\n<td>Precise dosing, sensitivities<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Full-spectrum<\/strong> extracts preserve the full profile of cannabinoids and terpenes present in the original plant. They contain trace amounts of THC, typically below 0.2% in legal EU products. For most users, this level of THC presents no psychoactive risk and no meaningful drug test risk, but this cannot be guaranteed for everyone, particularly at very high doses.<\/p>\n<p><strong>Broad-spectrum<\/strong> extracts undergo additional processing to remove THC while retaining other cannabinoids and terpenes. They are the pragmatic middle ground, preserving potential entourage effect benefits while addressing concerns about THC exposure.<\/p>\n<p><strong>Isolate<\/strong> is the purest form of cannabinoid with no other plant compounds. It is typically flavourless and odourless, making it easy to incorporate into other products.<\/p>\n<\/section>\n<section id=\"legal-status\">\n<h2>10. Legal status by cannabinoid<\/h2>\n<p>Cannabis legislation remains one of the most fragmented areas of consumer law globally. Here is a practical overview, but always verify your local regulations, as rules change frequently.<\/p>\n<h3>European Union<\/h3>\n<p>The EU operates under a dual framework. Industrial hemp cultivation is legal in member countries using approved cultivar varieties with less than 0.3% THC in the plant. CBD derived from these plants is regulated as a Novel Food, a designation applied by the European Food Safety Authority (EFSA) in 2019. This means CBD food supplements and food products must obtain Novel Food authorisation before being placed on the market in new product categories (the process is ongoing for many brands).<\/p>\n<p><strong>THC<\/strong> remains a controlled substance under the UN Single Convention in all EU member states. The threshold for enforcement in finished products varies: 0.2% is common but some countries apply 0.0% in food products.<\/p>\n<p><strong>CBG, CBN, CBC<\/strong> are generally not independently scheduled in most EU countries and are legal in hemp-derived products when THC is within legal limits.<\/p>\n<p><strong>Delta-8 THC and HHC (hexahydrocannabinol)<\/strong> and other novel semi-synthetic cannabinoids exist in a legal grey area. Several EU countries have moved to ban them explicitly. Treat with extreme caution and check current local law.<\/p>\n<h3>United Kingdom<\/h3>\n<p>The UK follows a similar framework post-Brexit, with CBD products regulated as Novel Foods by the FSA (Food Standards Agency). Products must appear on the FSA&#8217;s validated Novel Food list to be legally sold. THC is a Class B controlled substance; the limit in finished CBD products is 1 mg per container.<\/p>\n<h3>United States<\/h3>\n<p>The 2018 Farm Bill legalised hemp and hemp-derived CBD at the federal level when the plant contains less than 0.3% THC. However, the FDA has yet to establish a clear regulatory pathway for CBD in food and dietary supplements. THC (delta-9) remains federally scheduled, though many states have legalised it medically or recreationally. Delta-8 THC exists in a contested legal space: it is derived from hemp-sourced CBD but has been banned in over a dozen states.<\/p>\n<\/section>\n<\/div>\n<\/div>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Cannabinoids 101 Everything you need to know about what cannabinoids are, how they work, and why they matter: from plant chemistry to your body&#8217;s own endocannabinoid system. Table of Contents What are cannabinoids? How cannabinoids are made? The endocannabinoid system Phytocannabinoids: The main players Endocannabinoids: Your body&#8217;s own version Synthetic cannabinoids The entourage effect Cannabinoids [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"custom-page-template.php","meta":{"footnotes":""},"class_list":["post-47535","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/pages\/47535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/comments?post=47535"}],"version-history":[{"count":0,"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/pages\/47535\/revisions"}],"wp:attachment":[{"href":"https:\/\/hempika.com\/en\/wp-json\/wp\/v2\/media?parent=47535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}